Different isoforms of plasma phosphorylated tau (p-tau) may be early biomarkers of cognitive decline (cf. plasma total tau) [6, 38, 39], with different assay platforms able to differentiate AD from CU participants [40, 41]. This evidence concerns the gene MAPT and Alzheimer disease.